NucleBio’s New Prostac Test May Improve Diagnosis of Aggressive Prostate Cancer, Company Says

NucleBio’s New Prostac Test May Improve Diagnosis of Aggressive Prostate Cancer, Company Says
A new test called Prostac is able to accurately tell the difference between benign and aggressive prostate cancer, which has the potential to significantly improve men's healthcare, according to developer NucleoBio. "Prostac is a non-invasive, urine-based test that will resolve numerous flaws in existing prostate cancer screening methods," Charles Oyesile, MD, PhD, NucleoBio’s CEO and co-founder, said in a press release. The Prostate Specific Antigen (PSA) test is now the most common method for men with prostate cancer symptoms, and for those already diagnosed with the disease to monitor its progression. However, an elevation in blood PSA level may also occur in benign conditions, including harmless forms of prostate cancer. "Up to 75 percent of prostate-specific antigen tests given today return a false positive; the tests suggest there is prostate cancer when it's actually not. As a result, patients are being misdiagnosed, overtreated and overcharged,” Oyesile said, adding that false positives cause heightened anxiety and undue stress. “Prostac is going to drastically improve health care for men and dramatically disrupt the health care industry,” he said. According to NucleoBio, Prostac may eliminate the need for stress-inducing PSA screening, magnetic resonance imaging, digita
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *